Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016)

被引：0
|
作者：
Herrera-Abreu, Maria Teresa
Palafox, Marta
Asghar, Uzma
Rivas, Martin A.
Cutts, Rosalind J.
Garcia-Murillas, Isaac
Pearson, Alex
Guzman, Marta
Rodriguez, Olga
Grueso, Judit
Bellet, Meritxell
Cortes, Javier
Elliott, Richard
Pancholi, Sunil
Lord, Christopher J. [1 ,2 ]
Baselga, Jose
Dowsett, Mitch
Martin, Lesley-Ann
Turner, Nicholas C.
Serra, Violeta
机构：
[1] Inst Canc Res, CRUK Gene Funct Lab, London, England
[2] Inst Canc Res, Breast Canc Now Res Ctr, London, England
来源：
CANCER RESEARCH | 2016年 / 76卷 / 19期
关键词：
D O I：
10.1158/0008-5472.CAN-16-1853
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5907 / 5907
页数：1
相关论文
共 50 条
  • [21] Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
    Watt, April C.
    Goel, Shom
    BREAST CANCER RESEARCH, 2022, 24 (01)
  • [22] Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
    April C. Watt
    Shom Goel
    Breast Cancer Research, 24
  • [23] CDK4/6 inhibitor-mediatated radiosensitization of estrogen receptor positive breast cancer
    Pesch, Andrea M.
    Hirsh, Nicole
    Chandler, Benjamin C.
    Michmerhuizen, Anna R.
    Ritter, Cassandra L.
    Androsiglio, Marlie
    Wilder-Romans, Kari
    Liu, Meilan
    Gersch, Christina L.
    Larios, Jose M.
    Rae, James M.
    Speers, Corey W.
    CANCER RESEARCH, 2020, 80 (16)
  • [24] Radiosensitization of Estrogen Receptor Positive Breast Cancers with Short-Term CDK4/6 Inhibition
    Pesch, A.
    Hirsh, N.
    Chandler, B.
    Michmerhuizen, A. R.
    Wilder-Romans, K.
    Liu, M.
    Ritter, C.
    Androsiglio, M.
    Gersch, C.
    Larios, J.
    Pierce, L. J.
    Rae, J.
    Speers, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S57 - S58
  • [25] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
  • [26] The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
    Shah, Ami N.
    Cristofanilli, Massimo
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
  • [27] Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer
    Bayraktar, Soley
    Batoo, Sameer
    Al-Hattab, Eyad
    Basu, Sandeep
    Okuno, Scott
    Gluck, Stefan
    FUTURE ONCOLOGY, 2020, 16 (32) : 2661 - 2672
  • [28] CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
    de Melo Gagliato, Debora
    Buzaid, Antonio C.
    Manuel Perez-Garcia, Jose
    Llombart, Antonio
    Cortes, Javier
    CANCERS, 2020, 12 (09) : 1 - 19
  • [29] The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
    Ami N. Shah
    Massimo Cristofanilli
    Current Treatment Options in Oncology, 2017, 18
  • [30] CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor-Positive Advanced Breast Cancer?
    Shah, Mirat
    Nunes, Maria Raquel
    Stearns, Vered
    ONCOLOGY-NEW YORK, 2018, 32 (05): : 216 - 222
12345